<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132690</url>
  </required_header>
  <id_info>
    <org_study_id>PB-06-005</org_study_id>
    <nct_id>NCT01132690</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, double-blind trial to assess the safety and efficacy of taliglucerase
      alfa in untreated subjects (2 to &lt;18 years old) with Gaucher disease randomly assigned to
      treatment with one of two doses, 30 or 60 units/kg. Subjects will receive an intravenous (IV)
      infusion of taliglucerase alfa every two weeks. The total duration of treatment will be 12
      months. At the end of the 12-month treatment period eligible subjects will be offered
      enrollment in an open-label extension study if taliglucerase alfa is not commercially
      available.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
    <description>median and interquartile range for change from baseline in haemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chitotriosidase</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
    <description>Percent change from baseline in chitotriosidase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spleen Volume</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Spleen volume measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Count</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Mean and standard deviation of platelet count per cubic mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemokine (C-C Motif) Ligand 18 (CCL18)</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
    <description>Percent change from baseline in CCL18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Volume</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Liver volume measured by MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>30 units/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>60 units/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taliglucerase alfa</intervention_name>
    <description>Taliglucerase alfa for infusion every two weeks for 12 months</description>
    <arm_group_label>30 units/kg</arm_group_label>
    <arm_group_label>60 units/kg</arm_group_label>
    <other_name>prGCD, plant cell expressed glucocerebrosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 2 to &lt;18 years old.

          -  Diagnosis of Gaucher disease with leukocyte acid β-glucosidase activity ≤30% of the
             mean of the reference range for healthy subjects.

          -  Subjects who have not received enzyme replacement therapy (ERT) in the past or who
             have not received ERT in the past 12 months and have a negative
             anti-glucocerebrosidase antibody assay.

          -  Subjects who have not received substrate reduction therapy (SRT) in the past 12
             months.

          -  Subjects whose clinical condition, in the opinion of the investigator, requires
             treatment with enzyme replacement therapy (ERT).

        Exclusion Criteria:

          -  Currently taking another investigational drug for any condition.

          -  Presence of neurological signs and symptoms characteristic of Gaucher disease with
             complex neuronopathic features other than longstanding oculomotor gaze palsy.

          -  Presence of unresolved anemia due to iron, folic acid, or vitamin B12 deficiency

          -  Previous hypersensitivity reaction to Cerezyme® (imiglucerase) or Ceredase®
             (alglucerase).

          -  History of allergy to carrots.

          -  Presence of HIV, HBsAg or hepatitis C infections.

          -  Subject's parent(s) or legal guardian(s) are unable to understand the nature, scope
             and possible consequences of the study.

          -  Presence of any medical, emotional, behavioral or psychological condition that in the
             judgment of the Investigator would interfere with the subject's compliance with the
             requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Zimran, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C)</name>
      <address>
        <city>Barrio Sajonia Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morningside Medi-Clinic</name>
      <address>
        <city>Morningside</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Paraguay</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <results_first_submitted>October 28, 2014</results_first_submitted>
  <results_first_submitted_qc>November 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2014</results_first_posted>
  <disposition_first_submitted>April 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 13, 2014</disposition_first_posted>
  <last_update_submitted>November 10, 2014</last_update_submitted>
  <last_update_submitted_qc>November 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gaucher disease</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>30 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
        </group>
        <group group_id="P2">
          <title>60 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>30 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
        </group>
        <group group_id="B2">
          <title>60 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" spread="4.0"/>
                    <measurement group_id="B2" value="6.6" spread="3.1"/>
                    <measurement group_id="B3" value="8.2" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Paraguay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Religion</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Jewish - Ashkenazi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jewish - Non-Ashkenazi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non Jewish</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin</title>
        <description>median and interquartile range for change from baseline in haemoglobin</description>
        <time_frame>Every 3 months for 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
          <group group_id="O2">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <description>median and interquartile range for change from baseline in haemoglobin</description>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-0.3" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-0.1" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.3" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.5" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.2" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.4" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chitotriosidase</title>
        <description>Percent change from baseline in chitotriosidase</description>
        <time_frame>Every 3 months for 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
          <group group_id="O2">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Chitotriosidase</title>
          <description>Percent change from baseline in chitotriosidase</description>
          <units>Percent Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4" spread="23.5"/>
                    <measurement group_id="O2" value="-32.7" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.6" spread="19.8"/>
                    <measurement group_id="O2" value="-50.2" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.2" spread="18.7"/>
                    <measurement group_id="O2" value="-58.9" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.5" spread="17.5"/>
                    <measurement group_id="O2" value="-66.1" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spleen Volume</title>
        <description>Spleen volume measured by MRI</description>
        <time_frame>Baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
          <group group_id="O2">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Spleen Volume</title>
          <description>Spleen volume measured by MRI</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1218" spread="638.4"/>
                    <measurement group_id="O2" value="1023" spread="753.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="811.6" spread="409.6"/>
                    <measurement group_id="O2" value="524.0" spread="281.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Count</title>
        <description>Mean and standard deviation of platelet count per cubic mm</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
          <group group_id="O2">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Count</title>
          <description>Mean and standard deviation of platelet count per cubic mm</description>
          <units>platelets per cubic mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162667" spread="71838"/>
                    <measurement group_id="O2" value="99600" spread="42899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208167" spread="90747"/>
                    <measurement group_id="O2" value="172200" spread="89290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemokine (C-C Motif) Ligand 18 (CCL18)</title>
        <description>Percent change from baseline in CCL18</description>
        <time_frame>Every 3 months for 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
          <group group_id="O2">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Chemokine (C-C Motif) Ligand 18 (CCL18)</title>
          <description>Percent change from baseline in CCL18</description>
          <units>Percent Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.4" spread="15.3"/>
                    <measurement group_id="O2" value="-18.3" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.7" spread="11.9"/>
                    <measurement group_id="O2" value="-37.3" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.9" spread="13.0"/>
                    <measurement group_id="O2" value="-46.5" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.6" spread="19.4"/>
                    <measurement group_id="O2" value="-52.6" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Volume</title>
        <description>Liver volume measured by MRI</description>
        <time_frame>Baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
          <group group_id="O2">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Volume</title>
          <description>Liver volume measured by MRI</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1214" spread="424.7"/>
                    <measurement group_id="O2" value="991.7" spread="301.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1116" spread="366.9"/>
                    <measurement group_id="O2" value="849.1" spread="271.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>30 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
        </group>
        <group group_id="E2">
          <title>60 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior VP Development</name_or_title>
      <organization>Protalix Biotherapeutics</organization>
      <phone>+972-4-902-8100</phone>
      <email>einat@protalix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

